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ABSTRACT 
Plasmodium falciparum infection can abruptly progress to severe malaria and cerebral malar-
ia. Despite the current efficiency of antimalarial drugs in killing parasites, no specific effec-
tive treatment has been found for cerebral malaria. Thus, a new strategy targeting both para-
site elimination and endothelial cell protection is urgently needed in this field. In this study, 
we determined whether curcumin, which has blood-brain permeability, antioxidative activity 
and/or immunomodulation property, provided a potential effect on both parasite elimination 
and endothelial protection. Murine brain microvascular endothelial cells (bEnd.3; ATCC) 
were cocultured with Plasmodium falciparum-infected red blood cells (Pf-IRBC), peripheral 
blood mononuclear cell (PBMC) and platelets. Apoptosis of endothelial cells was demonstrat-
ed by annexin V staining. Interestingly, curcumin exhibited high efficiency of antimalarial ac-
tivity (IC50 ~10 µM) and decreased bEnd.3 apoptosis down to 60.0 % and 79.6 % upon pre-
treatment and co-treatment, respectively, with Pf-IRBC, platelets and PBMC. Our findings 
open up a high feasibility of applying curcumin as a potential adjunctive compound for cere-
bral malaria treatment in the future. 
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INTRODUCTION 
Cerebral malaria (CM) accounts for a 
significant proportion of the morbidity and 
mortality associated with malaria in chil-
dren with the age of less than five years. 
Despite a massive amount of experimental 
and clinical works, the pathophysiologic 
mechanisms of such complication are poor-
ly understood. Pathological studies in 
Southeast Asian adults dying from CM had 
shown a definitive association between se-
questration of Plasmodium falciparum-
infected red blood cell (Pf-IRBC) in the 
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brain and the coma resulted from CM se-
questration (Silamut et al., 1999).  
The symptoms of CM range from con-
fusion or stupor to obtundation, convulsions 
and deep coma with long-term neurological 
deficits such as cortical blindness. CM is 
associated with activation of immune cells 
and anticoagulant platelets, elevated pro-
inflammatory cytokine levels, and endothe-
lial damage (Miller et al., 1994). 
Undoubtedly, interaction between P. 
falciparum and the human host cells during 
malarial infection leads to pathogenesis of 
the disease. Then, parasite elimination is 
more beneficial in controlling the patholog-
ical condition. Conventional emergency 
treatment is based on intravenous admin-
istration of antimalarial drugs such as qui-
nine and artemisinin derivatives (van Hens-
broek et al., 1996). Artemisinin derivatives 
have many advantages over quinine, most 
notably a far better safety profile, with few-
er serious side effects. A large multicenter, 
multi-country, open-label randomized clini-
cal trial on the treatment of malaria in 
Southeast Asia definitively showed de-
creased mortality with artesunate (15 %) as 
compared with quinine (22 %) treatment 
(Dondorp et al., 2005). However, the use of 
antimalarial drugs such as artesunate, alt-
hough effective in global malaria control 
programs, is interrupted by high cost and 
limited supply (Butler, 2004). Therefore, 
identification of an antimalarial drug that is 
easy to produce, inexpensive, and low tox-
icity across a diverse population represents 
the ideal agent needed for global malaria 
control programs. 
Curcumin (diferuloylmethane) is a natu-
ral polyphenolic compound in the rhizome 
of the perennial herb turmeric, Curcuma 
longa Linnaeus. It is widely used as a die-
tary spice and coloring in cooking and as a 
herb in traditional Indian medicine (Sharma 
et al., 2005). Curcumin exhibits a wide 
range of pharmacological activities, includ-
ing anti-inflammatory, anti-carcinogenic, 
and anti-infectious activities. The anti-
inflammatory and anti-carcinogenic effects 
of curcumin largely depend on its antioxi-
dant activity. In addition, curcumin pos-
sesses potential activities against bacteria, 
fungi, and protozoa. Cytotoxic and parasiti-
cidal effects of curcumin on protozoan par-
asites have been demonstrated in cultures 
against Leishmania, Trypanosoma, Giardia, 
and Plasmodium falciparum (Koide et al., 
2002; Nose et al., 1998; Perez-Arriaga et 
al., 2006; Rasmussen et al., 2000; Saleheen 
et al., 2002). In vivo, curcumin also dis-
played potent activity against Plasmodium 
berghei, and it was synergistic with arte-
misinin (Reddy et al., 2005). However, 
study of curcumin on the combining para-
site killing and endothelial protection has 
not been elucidated yet. 
Herein, we investigated the effect of 
curcumin on parasite elimination and endo-
thelial protection using in vitro systems. 
Two approaches were used:  
1) antimalarial activity; and  
2) anti-apoptosis of curcumin upon brain 
endothelial cells exposure to Plasmodium 
falciparum-infected red blood cell (Pf-
IRBC) and influential factors (immune cells 
and platelets). 
 
MATERIALS AND METHODS 
Reagent 
Curcumin (Sigma Chemical, St. Louis, 
MO) was dissolved in 100 % dimethyl sul-
foxide (DMSO; Sigma Chemical) and 
stored in aliquots at -20 °C. Tocopherol was 
a generous gift from Prof. Supaluk Pracha-
yasittikul (Centre of Data Mining and Bio-
medical Informatics, Faculty of Medical 
Technology, Mahidol University). 
 
Plasmodium falciparum culture 
The Plasmodium falciparum strain TM-
267 was a generous gift from Prof. Ra-
chanee Udomsangpetch (Department of 
Pathobiology, Faculty of Science, Mahidol 
University). Plasmodium falciparum-
infected red blood cells (Pf-IRBC) were 
cultured in RPMI-1640 medium containing 
10 % human serum (HS), as described pre-
viously (Trager and Jensen, 1976). The par-
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asite culture was maintained at 37 °C with 
5 % CO2. Briefly, sorbitol-synchronized 
trophozoite-stage Pf-IRBC was purified us-
ing Percoll density-gradient centrifugation 
(Lambros and Vanderberg, 1979). Para-
sitemia was then adjusted to 50 % Pf-IRBC 
and hema-tocrit to 1, 3 and 5 % Hematocrit 
(Hct). The term of 50 % Pf-IRBC (or 50 % 
parasitemia) corresponds to approximately 
5-50 parasitized erythrocytes/HBMEC se-
questered in the microvasculature during 
human infections (MacPherson et al., 1985; 
Pongponratn et al., 1985; Silamut et al., 
1999). 
 
Brain endothelial cell culture 
Murine brain microvascular endothelial 
cells (bEnd.3; ATCC) were cultured in 
DMEM medium supplemented with 10 % 
fetal bovine serum, 0.7 mM L-glutamine, 
100 µg/ml penicillin, 100 U/ml streptomy-
cin, and 100 µg/ml gentamicin. The bEnd.3 
cells were maintained at 37 °C with 5 % 
CO2 before adjustment to 7.0×105 cells/cm2 
in 25 cm2 culture flasks (Costar) for further 
experiment. 
 
In vitro antimalarial assay on blood stage 
of P. falciparum 
Antimalarial activity of curcumin was 
evaluated against P. falciparum chloroquine 
resistant strain (TM 267) using the well-
accepted method (Satayavivad et al., 2004). 
P. falciparum culture was synchronized by 
using sorbitol-induced hemolysis according 
to the method of Lambros and Vanderberg 
(1979) to obtain ring stage-infected red 
blood cells and then incubated for 48 hours 
prior to the drug testing to avoid the effect 
of sorbitol. The experiments were started 
with synchronized suspension of 2 % Pf-
IRBC during ring stage. Parasites were sus-
pended with culture medium supplemented 
with 15 % human serum to obtain 10 % cell 
suspension. The parasite suspension was 
put onto a 96-well microculture plate; 
50 µL in each well and then added 50 µL of 
various concentrations of curcumin as fol-
lows: 0.01, 0.1, 1, 10 and 100 µM. The rate 
of parasite growth was observed for 4 days 
and each concentration was performed in 
triplicate. The percentage of parasitemia of 
control and curcumin-treated groups were 
examined by microscopic technique using 
methanol-fixed Giemsa stained thin smear 
blood preparation. The efficacy of curcu-
min was evaluated by determining the con-
centration that reduced the growth of para-
site by 50 % (IC50). Antimalarial drug; ar-
tesunate was used as positive control 
(Wongsrichanalai et al., 1999). 
 
Cytotoxic assay of curcumin 
Cytotoxic assay of curcumin was per-
formed using the modified method as pre-
viously described (Tengchaisri et al., 1998). 
The bEnd.3 cells were cultured in DMEM 
medium supplemented with 10 % fetal bo-
vine serum, 0.7 mM L-glutamine, 
100 µg/ml penicillin, 100 U/ml streptomy-
cin, and 100 µg/ml gentamicin. Briefly, 
bEnd.3 cells were seeded at 1×104 cells 
(100 µL) per well in a 96-well plate, and 
incubated in humidified atmosphere, 95 % 
air, 37 °C, 5 % CO2 until they reached 
100 % confluence. The bEnd.3 cells were 
incubated for 72 hours with various concen-
trations of curcumin. Then, cells were incu-
bated with MTT solution (1 mg/ml) for 4 
hours at 37 °C, 5 % CO2. After that, forma-
zan-salt generated by mitochondria of via-
ble cells as results of conversion of MTT 
was dissolved in 100 % DMSO and the ab-
sorbance was measured at 540 nm. IC50 
values were determined as the bioactive 
compounds concentrations at 50 % inhibi-
tion of the cell growth. 
 
Preparation of peripheral blood mononu-
clear cells 
This study was obtained IRB approval 
(MU-IRB 2012/058.2703) from the Com-
mittee on Human Rights Related to Human 
Experimentation, Mahidol University, 
Bangkok, Thailand. Informed consent was 
obtained from each individual before sam-
ples were taken. Peripheral blood from a 
healthy volunteer was collected in a sterile 
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tube containing heparin solution. The blood 
was mixed with phosphate-buffered saline 
(PBS) at a ratio of 1:1, followed by over 
layering on Histopaque 1077° (Sigma-
Aldrich, USA) and centrifugation at 400 g 
for 30 minutes. Peripheral blood mononu-
clear cells (PBMC) were collected from the 
interface, washed twice with PBS at 250 g 
for 10 minutes, and resuspended in DMEM 
medium supplemented with 10 % fetal bo-
vine serum, 0.7 mM L-glutamine, 
100 µg/ml penicillin, 100 U/ml streptomy-
cin, and 100 µg/ml gentamicin. The viabil-
ity of PBMC was determined using a 0.2 % 
(w/v) trypan blue dye exclusion assay. All 
experiments were performed at a PBMC vi-
ability of over 90 %. The PBMC were 
maintained in RPMI-1640 medium before 
adjustment to an optimal ratio of PBMC to 
bEnd.3 cells at 7.0×105 cells/cm2 to 7.0×105 
cells/cm2. This ratio did not show any affect 
to bEnd.3 cells for co-culturing, observed 
by AnnexinV assay (flow cytometry). 
 
Preparation of platelets  
Peripheral blood from a healthy volun-
teer was collected in sterile BD Vacutainer 
tubes (BD Biosciences, San Jose, CA, 
USA) containing 0.32 % sodium citrate. 
Platelet-rich plasma (PRP) was prepared by 
centrifugation at 200 g for 15 minutes at 
room temperature, and platelets were then 
pelleted by centrifugation of the PRP at 
2,000 g for 6 minutes. Following washing 
in prewarmed Tyrode buffer salt solution 
(TBSS), the platelets were maintained in 
the same buffer before adjustment to an op-
timal ratio of platelets to bEnd.3 cells at 
1.0×109 cells/cm2 to 7.0×105 cells/cm2. This 
ratio did not show any effect to bEnd.3 cells 
for co-culturing, observed by AnnexinV as-
say (flow cytometry). 
 
Apoptosis assay 
Parasitemia level and incubation period 
To assess the effects of Pf-IRBC on 
bEnd.3 cells apoptosis, cells were cultured 
(7.0×105 cells/cm2) in 25 cm2 culture flasks 
(Costar). The Pf-IRBC (trophozoite-stage) 
at 1, 3 and 5 % Hct, 50 % Pf-IRBC were 
added and incubated with the cells for 4 and 
20 hours in parasite culture medium. In 
control, the bEnd.3 cells were incubated 
with uninfected RBC (5 % Hct, uninfected 
RBC). After incubation, all factors were 
removed and the cells were washed twice 
with cold PBS and then resuspended in 1X 
binding buffer at a concentration of 1×106 
cells/ml. Then, 100 µl of the solution 
(1×105 cells) were transferred to a 5 ml cul-
ture tube. Annexin V-Alexa488/Propidium 
iodide (PI) was added to the solution. The 
solution was gently mixed with the cells 
and further incubated for 15 minutes at 
room temperature in the dark. The binding 
buffer was added to each tube at a volume 
of 400 µl. The apoptotic cells were ana-
lyzed by flow cytometry within 1 hour. 
 
Parasitemia and influential factors  
(immune cell and platelets) 
Since, CM involved with host responses 
such as activation of immune cells, inflam-
mation and interrupting blood coagula-
tion/thrombosis (Hunt et al., 2006; Miller et 
al., 2013; Miller et al., 1994; Turner 1997), 
we tested whether supplementation with 
immune cells (PBMC) and platelets would 
affect the viability of brain endothelial 
cells. 
The lowest-observed-adverse-effect le-
vel (LOAEL) of Pf-IRBC that causes an 
adverse alteration of cell viability was cho-
sen for this experiment. All factors: Pf-
IRBC, PBMC and platelets at: LOAEL of 
Pf-IRBC (% Hct, 50 % Pf-IRBC), 7.0×105 
cells/cm2 and 1×109 cells/cm2, respectively 
were added and incubated with the bEnd.3 
cells for 4 and 20 hours in parasite culture 
medium. In control, the bEnd.3 cells were 
incubated with uninfected RBC, PBMC and 
platelets at the same dose for 4 and 20 
hours. After incubation, all factors were 
removed and cells apoptosis was analyzed 
as abovementioned.  
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Effect of curcumin on endothelial  
protection 
To verify the capacity of curcumin on 
endothelial protection upon exposure to Pf-
IRBC and influential factors (immune cells 
and platelets), curcumin at IC50 (µM) was 
added to bEnd.3 cells cultivation in the pre-
treatment and co-treatment experiments. 
The efficiency of curcumin was com-
pared with well-known antioxidant com-
pound. In this case, tocopherol was chosen 
due to its capacity in modulating the effect 
of malarial infection (Adelekan et al., 1997; 
Das et al., 1996). The concentration of to-
copherol (~10 µM) was used to reflect level 
in serum that can be analyzed under clinical 
condition of severe malaria (Das et al., 
1996). Antimalarial drug; artesunate at IC50 
(nM) was used as positive control.  
 
Statistical analysis 
For quantitative analysis, all data were 
expressed as means ± SD. The significance 
of differences in the data was evaluated by 
the Mann-Whitney U tests. Correlation was 
calculated as Spearman rank correlations. 
Statisticl significance was evidenced at p < 
0.05. 
 
RESULTS 
Antimalarial activity of curcumin 
Antimalarial activity of curcumin was 
evaluated against P. falciparum chloroquine 
resistant strain (TM 267) compared with ar-
tesunate (served as a positive control). Our 
study showed that the artesunate inhibited 
parasite growth at ~10 nM, which is in 
good agreement with the previous study 
(Wongsrichanalai et al., 1999). Interesting-
ly, curcumin inhibited the growth of P. fal-
ciparum in a dose-dependent fashion; with 
an IC50 of ~10 µM (Figure 1). 
 
Cytotoxicity testing of curcumin 
The effects of curcumin on bEnd.3 cells 
were assessed to more than 95 % viability 
as confirmed by trypan blue exclusion as-
say. To identify the optimal concentration 
of curcumin, MTT assay was performed. In 
this study, DMSO was used as a solvent for 
curcumin, which did not show any cytotox-
ic effects. When curcumin was applied to 
cultured bEnd.3 cells for 72 hours, cells 
were almost 100 % viable in the presence 
of curcumin up to a concentration of 100 
µM. However, above this concentration, the 
cell viability showed less than 95 % (Figure 
2). 
 
 
Day
0 1 2 3 4 5
%
 P
ar
as
ite
m
ia
0
2
4
6
8
10
12
Control P.falciparum (TM267)
0.5% DMSO
Artesunate 10 nM
Curcumin 0.01 M
Curcumin 0.1 M
Curcumin 1 M
Curcumin 10 M
Curcumin 100 M
 
Figure 1: In vitro antimalarial activity of curcu-
min. Assays were done in triplicate and averag-
es from experiments are shown. Error bars in-
dicate standard deviation. 
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Figure 2: Cytotoxicity testing of curcumin. 
These data were representative of three inde-
pendent experiments that yielded similar re-
sults. 
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Role of parasitemia and incubation period 
on brain endothelial cell apoptosis 
To assess the effect of parasitemia and 
incubation period on brain endothelial ap-
optosis, Pf-IRBC (1, 3 and 5 % Hct, 50 % 
Pf-IRBC) at trophozoite-stage, were added 
to bEnd.3 cells grown in 25 cm2 culture 
flasks for 4 and 20 hours. Annexin V stain-
ing revealed that apoptosis of bEnd.3 cells 
was remarkably observed after 20 hours in-
cubation with Pf-IRBC compared with 4 
hours (Figure 3). Such evidences supported 
that the intensity of bEnd.3 cells apoptosis 
increased with time. Additionally, para-
sitemia levels induced a significant correla-
tion with the percentage of bEnd.3 cells 
apoptosis (r = 0.97, p < 0.001). Our data in-
dicated that Pf-IRBC induced bEnd.3 cells 
apoptosis depended on parasitemia level 
and incubation period (Table 1). 
 
Role of parasitemia and influential factors 
(immune cell and platelets) on brain  
endothelial cell apoptosis 
The lowest-observed-adverse-effect le-
vel (LOAEL) of Pf-IRBC that caused an 
adverse alteration of cell viability to apop-
tosis at 1 % Hct, 50 % Pf-IRBC was chosen 
for this experiment. Influential factors such 
as immune cell (PBMC) and platelets that 
involved with brain endothelial alteration in 
CM were chosen for in vitro study. 
Double-labeling Annexin V and Propid-
ium iodide showed that 0.95 % of annexin 
V–Alexa 488–positive cells and 7.90 % of 
double Annexin V and Propidium iodide–
positive cells were found in bEnd.3 cells 
cocultivated with Pf-IRBC, platelets and 
PBMC, whereas only 0.16 % and 0.07 % 
was detected in control bEnd.3 cells cocul-
tivated with uninfected RBC, platelets and 
PBMC (Figure 4). Our results demonstrated 
that increasing of bEnd.3 cells apoptosis 
depended on a synergistic effect between 
parasitemia and host cells; platelets and 
PBMC (Table 2). 
 
Effect of curcumin on endothelial protec-
tion 
Capacity of curcumin on endothelial 
protection against the consequence effect of 
cell apoptosis in the presence of Pf-IRBC, 
platelets and PBMC (control experiment) 
was evaluated by pre-treatment and co-
treatment with curcumin (10 µM) compared 
with tocopherol (10 µM), while artesunate 
(10 nM) was used as positive control. After 
20 hours incubation, it was found that ar-
tesunate inhibited Pf-IRBC, platelets and 
PBMC induced bEnd.3 cell apoptosis from 
10.4 % to 1.93 % and 0.41 % of pre-treat-
ment and co-treatment, respectively. Inter-
estingly, curcumin exhibited great efficien-
cy of endothelial protection in which reduc-
tion of endothelial cells apoptosis was de-
tected from 10.4 % to 4.16 % and 2.12 % 
on pre-treatment and co-treatment, respec-
tively, while tocopherol had lower protec-
tive effect (6.32 % and 7.68 % on pre-treat-
ment and co-treatment, respectively) as 
compared to the control experiment (Table 
3). Our data showed great efficiency of cur-
cumin on endothelial protection upon culti-
vation with Pf-IRBC, platelets and PBMC, 
which reduced bEnd.3 cells apoptosis at 
60.0 and 79.6 % of pre-treatment and co-
treatment, respectively, compared with the 
artesunate (81.4 and 96.1 %) (Table 3). 
 
DISCUSSION 
Antimalarial drugs are the cornerstone 
of malaria treatment; however, even the 
most used parasite-killing drug such as ar-
tesunate, could not prevent deaths among 
children with severe complications of ma-
laria, such as severe anemia (1 % mortality) 
(Marsh et al., 1995), acidosis (15 % mortal-
ity) or coma (18 % mortality) (Dondorp et 
al., 2010). Thus, rapid and effective parasite 
killing is insufficient to prevent death in se-
vere malaria. 
Beyond mechanically obstructing small 
vessels, adherent infected erythrocytes 
transduce pathologic endothelial activation 
signals that promote adhesion, coagulation 
and inflammation, and disrupt endothelial
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Figure 3: Effect of P. falciparum on bEnd.3 cells apoptosis upon cultivation with various percentages 
of hematocrit of Pf-IRBC for 4 (left panel) and 20 hours (right panel). Different conditions as (A) 
bEnd.3 cells control, (B) 1 % Hct, 50 % Pf-IRBC, (C) 3 % Hct, 50 % Pf-IRBC, (D) 5 % Hct, 50 % Pf-
IRBC, (E) 5 % Hct, Uninfected RBC were tested. The apoptotic cells were analyzed by flow cytometry. 
These figures were representative of three independent experiments that yielded similar results. 
(AnV–/PI–: vital cell, AnV+/PI–: early apoptotic, AnV+/PI+: late apoptotic and AnV-/PI+: dead cell) 
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Table 1: Effect of parasitemia level and incubation period on apoptosis induction of bEnd.3 cells via 
Plasmodium falciparum-infected red blood cells (Pf-IRBC) 
% Hematocrita 
% Apoptosis (range)b With-
ingroupc 
(P = 0.05)
Between-
groupd 
(P = 0.05)4 hours 20 hours 
 
1% Hct, 50% Pf-IRBC 
 
3% Hct, 50% Pf-IRBC 
 
5% Hct, 50% Pf-IRBC 
 
5% Hct, Uninfected RBC 
 
 
0.05 ± 0.07 
 
0.06 ± 0.02 
 
0.09 ± 0.06 
 
0.04 ± 0.02 
 
 
3.55 ± 0.29 
 
5.93 ± 0.15 
 
7.52 ± 0.11 
 
0.03 ± 0.01 
 
 
P < 0.05 
 
P < 0.05 
 
P < 0.05 
 
P > 0.05 
 
 
P < 0.05 
 
P < 0.05 
 
P < 0.05 
 
NA 
 
a Various percentages of hematocrit of 50 % Pf-IRBC 
b Data represented as mean of values from three independent experiments ± SD 
c Data were compared within group (4 hours vs 20 hours) 
d Data were compared with control (Uninfected RBC) at 20 hours 
 
 
 
Figure 4: Effect of Plasmodium falciparum-infected red blood cells (Pf-IRBC), Platelets and PBMC on 
bEnd.3 cells apoptosis. Different conditions as (A) Pf-IRBC+Platelets, (B) Pf-IRBC+PBMC, (C) Pf-
IRBC+Platelets+PBMC, (D) Uninfected RBC+Platelets+PBMC were tested. The bEnd.3 cells were 
cultured with Pf-IRBC, Platelets and PBMC at the condition of 1 % Hct, 50 % Pf-IRBC, 1×109 cells/cm2 
Platelets and 7.0×105 cells/cm2 PBMC for 20 hours. These figures were representative of three inde-
pendent experiments that yielded similar results (AnV–/PI–: vital cell, AnV+/PI–: early apoptotic, 
AnV+/PI+: late apoptotic and AnV-/PI+: dead cell). 
 
 
EXCLI Journal 2014;13:287-299 – ISSN 1611-2156 
Received: February 03, 2014, accepted: February 19, 2014, published: March 20, 2014 
 
 
295 
Table 2: Influence of Plasmodium falciparum-infected red blood cells (Pf-IRBC) and influential factors 
(Platelets and PBMC) on bEnd.3 cells apoptosis  
Influential factorsa 
% Apoptosis (range)b Within 
groupc 
(P = 0.05) 
Between 
groupd 
(P = 0.05) 4 hours 20 hours 
 
Pf-IRBC 
 
Pf-IRBC + Platelets 
 
Pf-IRBC + PBMC 
 
Pf-IRBC + Platelets + PBMC 
 
Uninfected RBC + Platelets + PBMC 
 
 
0.05 ± 0.07 
 
0.16 ± 0.01 
 
0.17 ± 0.15 
 
0.51 ± 0.05 
 
0.13 ± 0.02 
 
 
3.55 ± 0.29 
 
3.32 ± 0.23 
 
4.61 ± 0.12 
 
10.77 ± 0.54 
 
0.27 ± 0.30 
 
 
P < 0.05 
 
P < 0.05 
 
P < 0.05 
 
P < 0.05 
 
P > 0.05 
 
 
P < 0.05 
 
P < 0.05 
 
P < 0.05 
 
P < 0.05 
 
NA 
 
a Pf-IRBC, PBMC and Platelets were used at 1 % Hct, 50 % Pf-IRBC, 7.0×105 cells/cm2 and 1×109 cells/cm2, respectively 
b Data represent as mean of values from three independent experiments ± SD 
c Data were compared within group (4 hours vs 20 hours) 
d Data were compared with control (Uninfected RBC + Platelets + PBMC) at 20 hours 
 
function. Then, therapeutics that can modu-
late key endothelial functions need to be 
tested as an adjunctive treatment in severe 
malaria and CM. 
Here, this study successfully explored 
the effect of curcumin on parasite elimina-
tion and endothelial protection in vitro sys-
tems. We found that curcumin inhibited the 
growth of P. falciparum in a dose-depen-
dent fashion; with an IC50 of ~10 µM. Our 
study gave a result similar to other studies 
(Chakrabarti et al., 2013; Nandakumar et 
al., 2006; Reddy et al., 2005). Moreover, 
curcumin did not show any cytotoxic ef-
fects when applied to cultured bEnd.3 cells 
for a long period of time. 
Role of Pf-IRBC on brain endothelial 
cells apoptosis was investigated. Our find-
ings showed that Pf-IRBC induced bEnd.3 
cells apoptosis, which is amplified by para-
sitemia levels and incubation period (Table 
1). However, the mechanism of brain endo-
thelial cells apoptosis triggered by Pf-IRBC 
is still unclear. Recently, Pino and co-
workers (2003) reported that Pf-IRBC cy-
toadherence could modulate brain endothe-
lial expression of TNF-α superfamily genes 
and apoptosis-related genes (Bad, Bax, 
caspases and iNOS). In addition, Pf-IRBC 
adhesion to brain endothelial directly acti-
vated the Rho kinase signaling pathway and 
induced the production of reactive oxygen 
species (ROS) by endothelial cells, both 
pathways could potentially lead to cell 
death (Pino et al., 2003). 
However, a number of other mecha-
nisms has been proposed and Pf-IRBC 
might not be the only factor determining 
endothelial dysfunction during infection 
(Gitau and Newton, 2005). Several possible 
mechanisms can also cause endothelial dys-
function. The first is specific cell adhesion 
events (sequestration) and second includes 
adhesion-independent pathways, which 
may or may not require the presence of se-
questered parasites within the vessel. 
Such events might activate secondary 
signaling cascades and could induce toxic 
local microvascular environment such as 
hypoxia or metabolic competition. The re-
lease of soluble parasite products acts as 
toxins or autocrine for the regulation of en-
dothelial function due to cytokine release 
(Hunt and Grau, 2003) or other mediators 
released by host leukocytes. The supportive 
reason for this mechanism had been studied 
in the brain of CM cases. Transmigration of 
host leukocytes and over-expression of pro-
inflammatory cytokines tumor necrosis fac-
tor (TNF)-α, IL-1β and transforming 
growth factor (TGF-β) were observed in 
post-mortem studied (Brown et al., 1999). 
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Our study supported the role of host re-
sponse on endothelial dysfunction during 
malarial infection. We showed that increas-
ing of bEnd.3 cells apoptosis significantly 
depended on a synergistic effect between 
parasitemia and host cells; platelets and 
PBMC (Table 2). 
Undoubtedly, brain endothelial cells 
represent as a key interface between the P. 
falciparum and the human host during ma-
larial infection. Thus, a strategy combining 
parasite elimination and endothelial protec-
tion is of great interest. Our study showed 
the capacity of curcumin that possessed 
both antimalarial activity and endothelial 
protection upon cultivation with Pf-IRBC, 
platelets and PBMC in both pre-treatment 
and co-treatment in vitro (Table 3). 
In context of malaria, curcumin has 
been shown to possess moderate antimalar-
ial activity with IC50 value of 5–18 µM 
(Chakrabarti et al., 2013; Nandakumar et 
al., 2006; Reddy et al., 2005). Curcumin not 
only acts itself antimalarial activity but also 
implicates in many targets in CM as fol-
lows: 
i. Curcumin modulates NF-κB (nuclear 
factor κ beta), which plays a vital role in 
malaria. Pf-IRBC has been shown to in-
duce NF-κB regulated inflammatory 
pathway in human cerebral endotheli-
um. Antimalarial activity in curcumin 
against the blood phase of the life cycle 
may lead to its role in regulation of NF-
κB. Curcumin has been evidenced to 
reduce the production of proinflamma-
tory cytokines such as TNF, IL-12 and 
IL-6 in vitro (Golenser et al., 2006). It 
can be concluded that curcumin can ef-
fectively control inflammatory cascade 
as a result of host immune response in 
CM. 
ii. Curcumin inhibits expression of various 
cell surface adhesion molecules such as 
ICAM-1, VCAM-1 and endothelial leu-
kocyte adhesion molecule (ELAM-1) on 
endothelial cell (Kunnumakkara et al., 
2008). Curcumin inhibits adhesion of 
platelets to brain endothelial cells in 
vitro, which accumulates in brain ves-
sels in CM patients (Zhang et al., 2008). 
These data support the development of 
adjunctive therapies to reverse the path-
ophysiological consequences of cytoa-
dherence. 
iii. Curcumin inhibits histone acetyltrans-
ferase (HAT) that causes parasite chro-
matin modifications and has antiparasit-
ic effects (Cui and Miao, 2007). 
iv. Curcumin inhibits iNOS by suppression 
of IFN-γ and IL-12 production. iNOS 
has been shown to mediate production 
of ROS (Pan et al., 2000). 
v. Curcumin upregulates heme oxygenase-
1 (HO-1) gene and protein expression 
by protecting the brain endothelial cells 
from peroxide mediated toxicity as well 
as toxicity caused due to free heme. 
(Motterlini et al., 2000).  
vi. Curcumin suppresses C-Jun N terminal 
kinases (JNK) activation. JNK belongs 
to the family of mitogen activated ki-
nases (MAP kinases), which are activat-
ed in response to inflammatory cyto-
kines and stress conditions. Its activa-
tion induces the transcription-dependent 
apoptotic signalling pathway, resulting 
in cell death during experimental CM 
(Anand and Babu, 2011). 
vii. In a murine model of CM, the admin-
istration of curcumin results in partial 
alleviation of CM and delayed death 
(Waknine-Grinberg et al., 2010). 
Taken altogether, curcumin has been 
evidenced to possess both antimalarial ac-
tivity and endothelial protection. This can 
be proposed as an ideal antimalarial com-
pound especially for use in combination 
with antimalarial drugs such as artesunate 
not only to limit the use but also to over-
come the problems of high cost and drug 
resistance. In view of its abundance, non-
toxic nature compound, and exhibited ther-
apeutic effects in a variety of human dis-
eases, it will be useful to further investigate 
the feasibility of applying curcumin as low-
cost adjunctive antimalarial agents. 
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Table 3: Protection/neutralization effects of curcumin on bEnd.3 cells apoptosis upon cultivation with 
Pf-IRBC, Platelets and PBMC at 20 hours 
Treatment 
agentsa 
% Apoptosis (range)b % Apoptosis reductionc 
Pre-Treatment Co-Treatment Pre-Treatment Co-Treatment 
 
Curcumin 
 
Tocopherol 
 
Artesunate 
 
 
4.16 ± 0.16 
 
6.32 ± 0.16 
 
1.93 ± 0.08 
 
 
2.12 ± 0.15 
 
7.68 ± 0.37 
 
0.41 ± 0.03 
 
 
60.0 
 
39.4 
 
81.4 
 
 
79.6 
 
26.2 
 
96.1 
 
a Flour treatment agents: Curcumin (10 µM), Tocopherol (10 µM), Artesunate (10 nM) 
b Data were mean of values from three independent experiments ± SD 
c Data were compared with control experiment: Pf-IRBC + Platelets + PBMC (bEnd.3 cell apoptosis 10.4 ± 0.73 %) 
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